Review Article

Development of PI3Kγ selective inhibitors: the strategies and application

Dong-yan Gu1, Meng-meng Zhang2, Jia Li2, Yu-bo Zhou2, Rong Sheng1
1 College of Pharmaceutical Sciences, Zhejiang University, Hangzhou 310058, China
2 National Center for Drug Screening, State Key Laboratory of Drug Research, Shanghai Institute of Materia Medica, Chinese Academy of Sciences, Shanghai 201203, China
Correspondence to: Rong Sheng: shengr@zju.edu.cn,
DOI: 10.1038/s41401-023-01166-8
Received: 14 June 2023
Accepted: 4 September 2023
Advance online: 6 October 2023

Abstract

The γ isoform of Class I PI3Ks (PI3Kγ) is primarily found in leukocytes and is essential for the function of myeloid cells, as it regulates the migration, differentiation, and activation of myeloid-lineage immune cells. Thus, PI3Kγ has been identified as a promising drug target for the treatment of inflammation, autoimmune disease, and immuno-oncology. Due to the high incidence of serious adverse events (AEs) associated with PI3K inhibitors, in the development of PI3Kγ inhibitors, isoform selectivity was deemed crucial. In this review, an overview of the development of PI3Kγ selective inhibitors in the past years is provided. The isoform selectivity of related drugs was achieved by different strategies, including inducing a specificity pocket by a propeller-shape structure, targeting steric differences in the solvent channel, and modulating the conformation of the Asp-Phe-Gly DFG motif, which have been demonstrated feasible by several successful cases. The insights in this manuscript may provide a potential direction for rational drug design and accelerate the discovery of PI3Kγ selective inhibitors.

Keywords: PI3K; PI3Kγ inhibitors; isoform selectivity; drug development; rational drug design

Article Options

Download Citation

Cited times in Scopus